Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|October 10, 2024
Most Common Symptomatic Adverse Reactions of Cancer Treatments From US Drug Labels (2015-2021) to Inform Selection of Patient-Reported OutcomesErica G Horodniceanu, Tejaswi Datla, Meena N Murugappan, et al.
Seminars in Hematology|November 24, 2024
Modernizing multiple myeloma clinical trial eligibility to improve equity and inclusivity by hematological parametersLauren Merz, Monique Hartley-Brown, Maureen Achebe, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 28, 2021
Perspectives on Drug Development in Multiple Myeloma-Looking Forward to 2025Peter M Voorhees, Andrzej J Jakubowiak, Shaji K Kumar, et al.
Blood|May 4, 2023
Eligibility criteria and enrollment of a diverse racial and ethnic population in multiple myeloma clinical trialsBindu Kanapuru, Laura L Fernandes, Andrea Baines, et al.
Blood Advances|February 3, 2022
Analysis of racial and ethnic disparities in multiple myeloma US FDA drug approval trialsBindu Kanapuru, Laura L Fernandes, Lola A Fashoyin-Aje, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 16, 2024
FDA Approval Summary: Teclistamab-A Bispecific CD3 T-Cell Engager for Patients with Relapsed or Refractory Multiple MyelomaAndrea C Baines, Bindu Kanapuru, Jay Zhao, et al.
Journal of Geriatric Oncology|December 17, 2023
Patient-reported frailty phenotype (PRFP) vs. International Myeloma Working Group frailty index (IMWG FI) proxy: A comparison between two approaches to measuring frailtyMeena N Murugappan, Bellinda L King-Kallimanis, Vishal Bhatnagar, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|March 20, 2023
Measuring Frailty Using Patient-Reported Outcomes (PRO) Data: A Feasibility Study in Patients with Multiple MyelomaMeena N Murugappan, Bellinda L King-Kallimanis, Vishal Bhatnagar, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 19, 2023
FDA Analysis of Ineligibility for Acute Myeloid Leukemia Clinical Trials by Race and EthnicityDianne Pulte, Laura Fernandes, Guo Wei, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 23, 2022
FDA Approval Summary: Belantamab Mafodotin for Patients with Relapsed or Refractory Multiple MyelomaAndrea C Baines, Rachel Ershler, Bindu Kanapuru, et al.
Pageof 3